---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-304949"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2026-07-15T21:14:18+00:00"
generated_at: "2026-07-15T21:16:31.622104+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Decoy Therapeutics Stockholders Re-elect Directors, Approve Executive Pay and Auditor at 2026 Annual Meeting

## Summary
- Quorum of 42.4% (225,548 of 531,968 shares) present at July 14, 2026 Annual Meeting.
- Class II directors Patricia Gauthier, Jonathan Lieber, and Frederick E. Pierce re-elected with 23,204, 22,964, and 22,690 votes for, respectively.
- Non-binding advisory vote on named executive officer compensation passed with 21,278 votes for, 5,041 against, and 1,007 abstentions.
- Ratification of Ernst & Young LLP as independent auditor for FY2026 approved with 214,341 votes for, 9,584 against, 1,623 abstentions.

## SEC filing metadata
- accession: 0001193125-26-304949
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2026-07-15T21:14:18+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000119312526304949/0001193125-26-304949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000119312526304949/dcoy-20260714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-304949
- JSON: https://secwatch.observer/filing/0001193125-26-304949.json
- Plain text: https://secwatch.observer/filing/0001193125-26-304949.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.